SPR imaging biosensor for the 20S proteasome: sensor development and application to measurement of proteasomes in human blood plasma by Gorodkiewicz, Ewa et al.
ORIGINAL PAPER
SPR imaging biosensor for the 20S proteasome: sensor
development and application to measurement of proteasomes
in human blood plasma
Ewa Gorodkiewicz & Halina Ostrowska &
Anna Sankiewicz
Received: 11 May 2011 /Accepted: 1 July 2011 /Published online: 24 July 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract The 20S proteasome is a multicatalytic enzyme
complex responsible for intracellular protein degradation
in mammalian cells. Its antigen level or enzymatic
activity in blood plasma are potentially useful markers
for various malignant and nonmalignant diseases. We
have developed a method for highly selective determina-
tion of the 20S proteasome using a Surface Plasmon
Resonance Imaging (SPRI) technique. It is based on the
highly selective interaction between the proteasome’s
catalytic β5 subunit and immobilized inhibitors (the
synthetic peptide PSI and epoxomicin). Inhibitor concen-
tration and pH were optimized. Analytical responses,
linear ranges, accuracy, precision and interferences were
investigated. Biosensors based on either PSI and epox-
omicin were found to be suitable for quantitative
determination of the proteasome, with a precision of ±10%
for each, and recoveries of 102% and 113%, respectively,
and with little interference by albumin, trypsin, chymo-
trypsin, cathepsin B and papain. The proteasome also
was determined in plasma of healthy subjects and of
patients suffering from acute leukemia. Both biosensors
gave comparable results (2860 ng·mL-1 on average for
control, and 42300 ng·mL-1 on average for leukemia
patients).
Keywords SPRI.Biosensor.20S proteasome.PSI.
Epoxomicin.Plasma
Introduction
Proteasomes are responsible for the degradation of most
intracellular proteins in the cytoplasm and nucleus of all
eukaryotic cells [1, 2]. Such proteins include mutated or
damaged proteins, viral proteins, and many short-lived
proteins that control cell cycle progression, apoptosis and
the nuclear factor (NF)-κB transcriptional pathway; most of
them are first polyubiquitinated by and then directed to the
26S proteasomes for degradation [2]. The 26S proteasome
is a large multi-subunit complex (m. w. 2000 kDa)
composed of a central 20S catalytic core particle (20S
proteasome) and two 19S regulatory caps that recognize
ubiquitinated proteins. The 20S proteasome (m. w.
700 kDa) has a cylindrical structure composed of two outer
α-rings and two inner β-rings, each containing seven
distinct subunits (α1−7β1−7β1−7α1−7)[ 3, 4] (Fig. 1a). The
outer α-subunits control the entry of the substrate proteins
into the central catalytic chamber and bind the regulators,
while the three inner β subunits: β1, β2, and β5 contain an
N-terminal catalytically active threonine (Thr) residue and
harbor the caspase-like (Cas-L), trypsin-like (T-L) and
chymotrypsin-like (ChT-L) activities, respectively [5, 6].
Of these, the ChT-L activity is the rate-limiting step in
the degradation of intracellular proteins, including those
that determine tumor growth and survival and mediate
inflammatory conditions. A number of small molecule
inhibitors that primarily target the ChT-L activity of the
proteasome are described in the literature as possible anti-
cancer and anti-inflammatory agents [reviewed in 7–10].
One of them, bortezomib, is the first proteasome inhibitor
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patients [11], and is currently evaluated in clinical trials in
patients with other hematological malignancies or advanced
solid tumors [11–14]. Moreover, the 20S proteasomes
released into the circulation (circulating proteasomes) are
thought to be a novel biomarker for the prognosis and
monitoring of patients suffering from various types of
cancers, as well as other pathologies [reviewed in 15].
The most common method of detecting circulating
proteasomes in plasma or serum is the enzyme-linked
immunoabsorbent (ELISA) test employing antibodies di-
rected against the constitutive α6 (C2) subunits of the 20S
proteasome [16–23]. This method allows the quantitative
determination of the intact 20S proteasome complexes,
small proteasomal subunit fragments and free subunits in
plasma or serum (i.e. total concentrations of circulating
proteasomes). Unfortunately, techniques and antibodies
used in this assay differ among investigators, so that results
derived from different studies cannot be easily compared.
An alternative method for circulating proteasome assay
consists in measuring the ChT-L activity using the fluoro-
genic peptide substrate in the presence of an artificial
activator sodium dodecyl sulfate (SDS) [24–27]. Although,
the specificity of this assay was confirmed with highly
selective proteasome inhibitors, the method allows for the
detection of only the intact 20S proteasome complexes,
since free catalytic subunits are enzymatically inactive.
Surface Plasmon Resonance Imaging (SPRI) is a power-
ful technique for detecting biologically active species [28–
32], including papain and lysosomal proteases [33–37]. So
far, this method has not been applied to the determination of
20S proteasomes.
The aim of this study was to develop an SPRI biosensor
for 20S proteasome, and to evaluate the sensor applicability
for the determination of 20S proteasome concentration in
human blood plasma. Additionally, Atomic Force Micros-
copy (AMF) was used for observation of a chip surface
after creation of subsequent layers. AFM enables the
observation of the surface of the biosensor at nm range.
For the sensor development, a highly selective interaction
between catalytic β5 subunit harboring the ChT-L activity
and immobilized inhibitors: Z-Ile-Glu(OBut)-Ala-Leu-H
(PSI) or epoxomicin was applied (Fig. 1b). Being a peptide
aldehyde, PSI binds covalently to the N- terminal Thr1Oγ
located on β5 subunits, and powerfully and reversibly
blocks the ChT-L activity (IC50 250 nM) of the 20S
proteasome [7, 9, 38]. Epoxomicin, an active microbial
α’,β’ epoxyketone peptide, is a strong irreversible inhibitor
of the 20S proteasome ChT-L activity (IC50 >200 nM) that
binds covalently to the N-terminal catalytic Thr1Oγ to form
a stable morpholino adduct [7–9, 39]. Both, PSI and
epoxomicin have been commonly used to explore the role
of the proteasomes in physiological and pathological
processes [reviewed in 7, 9, 10].
Experimental
Reagents
20S proteasome (mammalian) (12 mg·mL-1 concentration
in solution of composition: 20 mM Tris-HCl. pH 7.5, 1 mM
EDTA, 1 mM DTT, 1 mM sodium azide) ( AFFINITI
Research Products Ltd, Mamhead, United Kingdom, www.
affinity-res.com), Z-Ile-Glu(OBut)-Ala-Leu-H (PSI)
(C32H50O8N4, 618.77 Da), epoxomicin (EPO)
(C28H50N4O7, 554.73 Da) (BIOMOL, Lörrach, Germany,
www.biomol.com), cysteamine hydrochloride, cathepsin B
from human placenta, trypsin from the human pancreas, α-
chymotrypsin from the human pancreas, human albumin,
papain from carica papaya, N-Ethyl-N’-(3-dimethyl amino-
propyl) carbodiimide (EDC), HEPES sodium salt (all
SIGMA, Steinheim, Germany, www.sigmaaldrich.com), N-
Hydroxysuccinimide (NHS) (ALDRICH, Munich, Germany,
www.sigmaaldrich.com) were used, as well as dichloroeth-
ane of HPLC grade (FLUKA, Munich, Germany, www.
sigmaaldrich.com), absolute ethanol, sodium hydroxide,
sodium chloride, sodium carbonate, sodium phosphate,
potassium phosphate, sodium acetate, potassium chloride,
magnesium chloride, (all POCh, Gliwice, Poland, www.
poch.com.pl), acetic buffer pH=4.99–5.57, HBS-ES solution
pH=7.4 (0.01 M HEPES, 0.15 M sodium chloride, 0.005%
Fig. 1 Structure of the 20S
proteasome (a) and chemical
structure of proteasome inhibi-
tors (b) targeting the catalytic
β5 subunit, used for the sensor
development. ChT-L,
chymotrypsin-like activity;
Cas-L, caspase like activity; T-L
trypsin like activity
178 E. Gorodkiewicz et al.Tween 20, 3 mM EDTA), Phosphate Buffered Saline (PBS)
pH=7.4 (BIOMED, Lublin, Poland, www.biomed.lublin.pl),
phosphate buffer pH=7.17–8.04, and carbonate buffer pH=
8.50–9.86. Photopolimer ELPEMER SD 2054, hydrophobic
protective paint SD 2368 UV SG-DG (PETERS, Kempen,
Germany, www.peters.de) Chemicals were used as received.
Aqueous solutions were prepared with filtered milliQ water
(Simplicity®MILLIPORE).
Chip preparation
Gold chips were manufactured as described in a previous
paper [33, 34]. Briefly, the gold surface of the chip was
covered with photopolymer and hydrophobic paint. 9×12
free gold surfaces were obtained. Using this chip, nine
different examined solutions can be simultaneously mea-
sured without mixing the tested solutions. Twelve single
SPRI measurements can be performed from one solution.
Inhibitor immobilization
Chips were rinsed with ethanol and water and dried under a
stream of nitrogen. They were then immersed in 20 mM of
cysteamine ethanolic solutions for 2 h and after rinsing with
ethanol and water dried again under a stream of nitrogen
[34]. Epoxomicin or PSI at a concentration of 80 nM, each,
were activated with NHS (50 mM) and EDC (200 mM) in a
carbonate buffer (pH=8.5) environment, and was then
placed on the thiol-modified surface and incubated at 37 °C
for 1 h.
SPRI measurements
SPRI measurements for the protein biosensor array were
performed as described elsewhere [34]. The signal was
measured twice on the basis of registered images, after
immobilisation of the inhibitor and then after interaction
with 20S proteasome. The SPRI signal, which is propor-
tional to coupled biomolecules, was obtained from subtrac-
tion between the signal before and after interaction with a
biomolecule for each spot separately. Thus, the SPRI signal
was integrated over the spot area. NIH Image J version 1.32
software was used to evaluate the SPRI images in 2D form.
Measurement of 20S proteasome concentration in human
blood plasma
Plasma samples from healthy adult donors (n=9) and
patients with acute leukemia (n=9) were supplied by the
Department of Hematology, Medical University of Bialys-
tok, Poland. Patients and healthy donors who were included
in the project were informed and their agreement was
Fig. 2 Dependence of SPRI signal (Arbitrary Units) of inhibitor (PSI
or EPO)- 20S proteasome complex on inhibitor concentration. 20S
proteasome concentration: 8 nM. Initial pH of proteasome solution:
7.4. (a) EPO– epoxomicin; (b) PSI – Z-Ile-Glu(OBut)-Ala-Leu-H
Fig. 4 Dependence of SPRI signal (Arbitrary Units) on 20S
proteasome concentration immobilized on inhibitor (80 nM) (a) EPO
(epoxomicin) and (b) PSI (Z-Ile-Glu(OBut)-Ala-Leu-H) and linear
section of curves (a) EPO and (b) PSI; concentration range 2–10 nM.
Initial pH value of proteasome solution: 7.4.
Fig. 3 Dependence of SPRI signal (Arbitrary Units) of inhibitor –
20S proteasome complex on pH. Initial inhibitor (a) EPO (epoxomi-
cin) or (b) PSI (Z-Ile-Glu(OBut)-Ala-Leu-H) concentration: 80 nM.
Initial 20S proteasome concentration: 8 nM
Sensor development and application for measurement of proteasomes 179obtained. Approval for this study was obtained from the
Local Ethics Committee. Plasma samples were 10-times
diluted with PBS buffer.
The drops of plasma were transferred onto the chip surface
for 10 min. A whole section of 12 spots was covered. The
surface was washed with distilled water 10-times and after
drying, the SPRI measurement was performed. An average
value taken from 12 pairs of measurements was considered as
a single result. Concentration was evaluated from the
calibration curve of 20S proteasome.
Statistical analysis
All the results are given as the mean ± standard error of the
mean (SEM). Avalue of p<0.05 was considered significant.
Results and discussion
In order to select the best conditions for 20S proteasome
determination by SPRI, the investigation was performed
within an inhibitor concentration range of 20 to 200 nM at
constant 20S proteasome concentration (8 nM). A series of 9
inhibitor solutions, pre-activated with NHS and EDC, were
transferredontodifferentpointsofthechipsurface,whichwas
previously modified with cysteamine. Inhibitor (PSI or EPO)
was immobilised during this treatment. The chip was then
treated with the 20S proteasome solution (8 nM) for 10 min,
rinsed with HBS-ES buffer and dried. The SPRI measurement
was performed. Each solution was put on a field (each of 12
measuring points). The results are given in Fig. 2.
The obtained curve is an isotherm type, with the plateau
of the signal for PSI or epoxomicin concentration above
60 nM. A concentration of inhibitor equal to 80 nM was
selected as optimal for further investigation.
Influence of solution pH on the interaction process
The influence of pH of the 20S proteasome solution on the
SPRI signal was studied for 9 different pH values (within the
range 4.99–9.5), under conditions of constant concentrations of
20S proteasome (8 nM) andinhibitor (80nM).Solutions of PSI
or epoxomicin pre-activated with EDC and NHS, were
transferred onto different points of a chip which was previously
modified with cysteamine. In this manner the inhibitor was
immobilised onto the chip surface. The chip was then treated
with20Sproteasomesolutions(8nM)withdifferentpHvalues,
for10min.TheresultsareshowninFig.3. As is apparent from
the diagram, the maximum of the SPRI signal for inhibitor
(PSI and EPO)-20S proteasome complex is located between
7.0 and 8.0. On this basis, the value of pH=7.4 was selected
as optimal for further investigation.
Table 1 Influence of various proteins (albumin, trypsin, chymotrypsin, cathepsin B or papain) on 20S proteasome determination by SPRI sensors.
Inhibitor concentration was 40 nM and concentration of 20S proteasome was 4 nM
Protein Cproteasome/ Cprotein Sensor on PSI inhibitor Sensor on EPO inhibitor
Added [nM] Found [nM] Recovery [%] Added [nM] Found [nM] Recovery [%]
Albumin 1:100 4.0 4.07±0.18 102 4.0 4.31±0.21 108
1:1000 4.0 3.79±0.15 95 4.0 4.28±0.25 107
1:10000 4.0 4.12±0.21 103 4.0 3.97±0.13 99
Trypsin 1:100 4.0 4.25±0.18 106 4.0 4.16±0.11 104
1:1000 4.0 4.04±0.04 101 4.0 4.03±0.16 101
Chymotrypsin 1:100 4.0 3.94±0.22 98 4.0 4.29±0.11 107
1:1000 4.0 4.21±0.17 105 4.0 4.19±0.15 105
Cathepsin B 1:100 4.0 3.97±0.19 99 4.0 4.12±0.15 103
1:1000 4.0 4.06±0.14 102 4.0 4.13±0.17 103
Papain 1:100 4.0 4.17±0.15 104 4.0 3.98±0.11 99
1:1000 4.0 4.05±0.16 101 4.0 4.27±0.13 107
Table 2 Precision and recovery of concentration measurement of 20S proteasome
No of meas. Added [nM] Found [nM] Recovery [%] S.D. [nM] Confidence limit
(95%) [nM]
20S proteasome immobilized on PSI 24 4.00 4.10 102 0.41 0.27
20S proteasome immobilized on EPO 24 4.00 4.51 113 0.40 0.26
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concentration. Calibration curves
The response of the analytical SPRI signal for 20S proteasome
concentration was measured within a range of concentration
between 2 and 25 nM. The chip surface was covered by a
monolayer of cysteamine and a layer of immobilized PSI and
epoxomicin (80 nM). The chip was then treated with the 20S
proteasome solution. The time of interaction was 10 min. The
experiments were performed at pH=7.4. The obtained calibra-
tion curve is shown in Fig. 4. As can be seen in this figure, all
calibration curves are of an isotherm type. The roughly linear
sections of these curves are within a range of 2 and 10 nM
and are useful analytically (Fig. 4). The plateau of the curve
corresponds to saturation of active points of the sensor. The
detection limit calculated on the 3 S.D. basis is equal to
0.16 nM for PSI inhibitor and 0.27 nM for epoxomicin.
Selectivity of the inhibitor-20S proteasome interaction
PSI is a highly selective inhibitor of the ChT-L activity of
the proteasome. However, at 10-times higher concentration
Fig. 5 AFM pictures of bare
gold (a), cysteamine (b), EPO
(c), PSI (d), 20S proteasome on
EPO (e) and on PSI (f)
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contrast, epoxomicin even at a concentration as high as
50 μM does not inhibit any proteases, including calpain,
cathepsins, trypsin, chymotrypsin, papain [8, 39].
In order to be sure that the interaction between inhibitor
(PSI or epoxomicin) and 20S proteasome is selective and
that the sensor does not react with the other proteins, the
chip containing immobilised inhibitor was treated with
mixtures of 20S proteasome – albumin, 20S proteasome –
trypsin, 20S proteasome – chymotrypsin, 20S proteasome –
cathepsin B and 20S proteasome – papain mixtures. Various
excesses of albumin within the range from 1:100 to
1:10000 were examined. Excesses of trypsin, chymotryp-
sin, cathepsin B and papain were 1:100 and 1:1000. Results
are shown in Table 1. No influence of albumin, trypsin,
chymotrypsin, cathepsin B or papain on the results of
determination of 20S proteasome even at a 1000-fold
excess using SPRI sensors was observed. Thus both
sensors’ high selectivity was confirmed.
Precision of the developed method for 20 S proteasome
determination
Precision of the developed method was tested under
optimal conditions, i.e. pH=7.4 and inhibitor (PSI or
EPO) concentration at the chip preparation stage equal to
80 nM. The precision of 20S proteasome determination was
tested for the concentration 4 nM. The results are shown in
Table 2. Standard deviation and the confidence limit,
assuming that the confidence level equals 95%, are
relatively high. This indicates that the developed biosensors
have a relatively low precision. However, the effect of
relatively poor precision is compensated by a large number
of repetitions, as the developed sensor is an array of 2×12
measuring spots. Therefore, recoveries of spikes are good
(PSI) or acceptable (EPO).
Atomic force microscopy (AFM) measurements
AFM was used to confirm the creation of subsequent
layers: gold, thiol (cysteamine), inhibitor (PSI or EPO) and
20S proteasome. Pictures were taken of bare gold (Fig. 5a),
cysteamine (Fig. 5b), EPO (Fig. 5c) PSI (Fig 5d) and 20S
proteasome on EPO and PSI (Fig. 5e and f). The presented
AFM pictures confirm that the described stages of the
creation of each layer on the biosensor surface has really
taken place. This may be concluded on the basis of the
creation of different structures after each stage.
Determination of 20S proteasome concentration in blood
plasma samples
Blood plasma samples from 9 healthy volunteers and 9
patients suffering from acute leukaemia at the blast stage
were analysed for 20S proteasome concentration using the
developed sensors based on inhibitors PSI or EPO. The
results of measurements were evaluated on the basis of a
calibration graphs, and are given in Table 3. In order to
have results comparable with the literature, the results were
recalculated from nM to ng·mL-1. In healthy subjects, the
mean value of plasma 20S proteasome concentration was
established as 2870±730 ng·mL-1 for the epoxomicin-
based biosensor and 2850±700 ng·mL-1 for the PSI
biosensor. All patients with acute leukemias had increased
plasma 20S proteasome concentration, with mean values
being as high as 41600±8570 ng·mL-1 for the epoxomicin-
based biosensor and 43000±10400 ng·mL-1 for the PSI
biosensor. The finding that plasma 20S proteasome con-
centrations measured using two biosensors were very
similar enhances the credibility of the results.
The results for healthy subjects are, in general, consistent
with those obtained by other investigators, who, using
ELISA-based assay have demonstrated that the average
Sample number 20S proteasome concentration in blood plasma [ng·mL-1]
Healthy donors Patients with acute leukemia
EPO sensor PSI sensor Type of leukemia EPO sensor PSI sensor
1 860±330 660±200 ALL 59700±3200 59500±3400
2 4150±850 3880±900 ALL 24000±2800 19900±2700
3 1800±700 2040±800 ALL 26100±2200 27800±3400
4 2520±750 2740±700 ALL 53100±2200 57100±3200
5 3800±800 3610±950 ALL 36500±1200 33900±2000
6 3610±800 3100±800 ALL 48600±4100 44500±4400
7 3500±850 3780±850 ALL 48200±5100 61600±5100
8 1980±750 2200±800 AML 49700±3800 54800±3900
9 3600±900 3630±950 AML 28100±3300 27900±3800
Mean value 2870±730 2850±700 41600±8570 43000±10400
Table 3 20S proteasome con-
centration in blood plasma of
healthy donors and patients with
acute lymphoblastic (ALL) and
myeloblastic (AML) leukemias
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are between 2100 and 2600 ng·mL-1 [17–19, 21]. However,
it should be mentioned that other groups of investigators
have demonstrated that 20S proteasome antigen concentra-
tion in plasma or serum from normal subjects was less than
400 ng·mL-1 [16, 20, 40]. Furthermore, the mean value of
plasma 20S proteasome concentrations measured by SPRI
in patients with acute leukemia was up to 15 times higher
as compared to plasma of control persons, whereas the
mean values of serum or plasma proteasome concentrations
determined by ELISA in patients suffering from the same
types of tumor was about 8-fold [16] or only 2-fold higher
as compared to healthy subjects [18]. It is also worth noting
that Wada et al [16] reported a large variability in 20S
proteasome antigen concentration in the plasma of patients
with acute leukemia (i.e. 2900±2569 ng·mL-1). No such
variability in elevated plasma 20S proteasome concentra-
tion was observed using SPRI biosensors. Based on this
data, it appears that the SPRI technique can be more
suitable and more clinically useful than ELISA-based assay
for measurements of 20S proteasome concentration in
human blood plasma.
Conclusions
Two selective SPRI array biosensors for the determination
of 20S proteasome concentration have been developed. The
sensors work on the basis of a highly selective reaction
between immobilised PSI or epoxomicin inhibitors and 20S
proteasome in solution. Under optimised conditions, both
sensors exhibit selectivity to 20S proteasome, and the
precision and accuracy is well suited to protein complex
determination. The sensor can be used for the determination
of 20S proteasome in human plasma, and possibly other
biological material.
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